April 2014 Webinar: Alphabet Soup – Making Sense out of KRAS, BRAF and Tumor Tests

Have you ever heard any of these acronyms, and wondered what they stand for and how they can affect your treatment plan?  This webinar is designed to help patients better understand biomarkers, and how these biomarkers can affect the treatment options patients receive. We’ll discuss the basic understandings of a cancer cell lives, and how it…  Read More

Personalizing Personalized Medicine

On Monday, April 25th, Fight Colorectal Cancer held a free patient webinar that tackled the somewhat complex but fascinating topic of personalized medicine. Personalized medicine is what the cancer community calls treatments that are tailored to each patient’s genetic makeup. It is the future of cancer care and in some cases, it is already making a…  Read More

Value of KRAS and BRAF Mutations in Forecasting Survival

For stage II and III colon cancer, a tumor mutation in the KRAS gene does not impact either relapse-free survival or overall survival. BRAF mutations, which are less common, don’t help with prognosis for relapse-free survival, but do provide information about overall survival in some tumors.   Patients with BRAF mutations and microsatellite-low or stable tumors had…  Read More

Another Gene Found Linked to Lack of Erbitux/Vectibix Response

Another mutated gene has been discovered that appears to cause resistance to treatment with the EGFR inhibitors Erbitux® (cetuximab) and  Vectibix™ (panitumumab). Only a fraction of patients who receive Erbitux or Vectibix respond to it.  There is now convincing evidence that the 30 to 40 percent of colorectal cancer patients whose tumors have mutated KRAS genes…  Read More